rapamune, mycophenolate mofetil and steroid + tacrolimus, sirolimus and steroid
Pre-clinicalCompleted 0 watching 0 views this week💤 Quiet
22
Development Stage
1
Pre-clinical2
Phase 13
Phase 24
Phase 35
ApprovedIndication / Disease
Absence; Kidney
Conditions
Absence; Kidney
Trial Timeline
Aug 1, 2009 → Jul 1, 2014
NCT ID
NCT01005706About rapamune, mycophenolate mofetil and steroid + tacrolimus, sirolimus and steroid
rapamune, mycophenolate mofetil and steroid + tacrolimus, sirolimus and steroid is a pre-clinical stage product being developed by Pfizer for Absence; Kidney. The current trial status is completed. This product is registered under clinical trial identifier NCT01005706. Target conditions include Absence; Kidney.
Hype Score Breakdown
Clinical
5
Activity
2
Company
9
Novelty
2
Community
1
Clinical Trials (1)
| NCT ID | Phase | Status |
|---|---|---|
| NCT01005706 | Pre-clinical | Completed |
Competing Products
9 competing products in Absence; Kidney
| Product | Company | Stage | Hype Score |
|---|---|---|---|
| topiramate | Johnson & Johnson | Phase 2 | 52 |
| Idelalisib | Gilead Sciences | Pre-clinical | 22 |
| Brivaracetam Film-coated tablet + Brivaracetam oral solution | UCB | Phase 3 | 74 |
| Brivaracetam Film-coated tablet + Brivaracetam oral solution | UCB | Phase 3 | 74 |
| Levetiracetam | UCB | Phase 2 | 49 |
| Brivaracetam | UCB | Phase 3 | 74 |
| Sativex and rifampicin + Sativex and rifampicin + Sativex and ketoconazole + Sativex and ketoconazole + Sativex and omeprazole + Sativex and omeprazole | Jazz Pharmaceuticals | Phase 1 | 30 |
| Cannabidiol (Epidiolex) | Jazz Pharmaceuticals | Approved | 82 |
| BMB-101 | Bright Minds Biosciences | Phase 2 | 47 |